Clinical data | |
---|---|
Trade names | Incruse Ellipta |
Other names | GSK573719A |
License data | |
Routes of administration | Inhalation ( DPI) |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~89% [3] |
Metabolism | Liver ( CYP2D6) |
Elimination half-life | 11 hours |
Excretion | Feces (58%) and urine (22%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.166.375 |
Chemical and physical data | |
Formula | C29H34BrNO2 |
Molar mass | 508.500 g·mol−1 |
3D model ( JSmol) | |
| |
|
Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) [4] [5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol. [6]
It is on the World Health Organization's List of Essential Medicines. [7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [8] [9]
Clinical data | |
---|---|
Trade names | Incruse Ellipta |
Other names | GSK573719A |
License data | |
Routes of administration | Inhalation ( DPI) |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~89% [3] |
Metabolism | Liver ( CYP2D6) |
Elimination half-life | 11 hours |
Excretion | Feces (58%) and urine (22%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.166.375 |
Chemical and physical data | |
Formula | C29H34BrNO2 |
Molar mass | 508.500 g·mol−1 |
3D model ( JSmol) | |
| |
|
Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) [4] [5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol. [6]
It is on the World Health Organization's List of Essential Medicines. [7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [8] [9]